Skip to main content
U.S. flag

An official website of the United States government

Selecting for neurogenic potential as an alternative for Alzheimer’s disease drug discovery

Bibliographic

Year of Publication:
2016
Contact PI Name:
David Schubert
Contact PI Affiliation:
The Salk Institute for Biological Studies, Cellular Neurobiology, La Jolla, California, USA
Co-Authors:
Marguerite Prior, Joshua Goldberg, Chandramouli Chiruta, Catherine Farrokhi, Mariya Kopynets, Amanda J. Roberts
Primary Reference (PubMED ID):
Funding Source:
Bruce Ford and Anne Smith Bundy Foundation
California Institute for Regenerative Medicine (CIRM)
Fritz B. Burns Foundation
Hewitt Foundation
National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)
Study Goal and Principal Findings:

Introduction: Neurons die in Alzheimer's disease (AD) and are not effectively replaced. An alternative approach to maintain nerve cell number is to identify compounds that stimulate the proliferation of endogenous neural stem cells in old individuals to replace lost neurons. However, unless a neurogenic drug is also neuroprotective, the replacement of lost neurons will not be sufficient to stop disease progression.

Methods: The neuroprotective AD drug candidate J147 is shown to enhance memory, improve dendritic structure, and stimulate cell division in germinal regions of the brains of very old mice. Based on the potential neurogenic potential of J147, a neuronal stem cell screening assay was developed to optimize derivatives of J147 for human neurogenesis.

Results: The best derivative of J147, CAD-031, maintains the neuroprotective and memory enhancing properties of J147, yet is more active in the human neural stem cell assays.

Discussion: The combined properties of neuroprotection, neurogenesis, and memory enhancement in a single drug are more likely to be effective for the treatment of age-associated neurodegenerative disorders than any individual activity alone.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
J147
Therapeutic Target:
ATP Synthase F1 Subunit alpha (ATP5F1A)
Therapy Type:
Small Molecule
Therapeutic Agent:
CAD-031
Therapeutic Target:
Multi Target
Therapy Type:
Small Molecule
Therapeutic Agent:
Donepezil
Therapeutic Target:
Acetylcholinesterase

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
Not Reported
Species:
Mouse
Model Type:
Non-transgenic
Strain/Genetic Background:
C57BL/6J

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Contextual Fear Conditioning
Elevated Plus Maze
Exploratory Activity
Object Place Recognition
Histopathology
beta Amyloid Deposits
Immunochemistry
Brain-beta Amyloid Deposits
5-bromo-2’-deoxyuridine (BrdU)
Doublecortin (DCX)
Microscopy
Cell Count
Dendritic Length
Dendritic Spine Density
Dendritic Spine Number
Cell Biology
Cell Proliferation
Neurogenesis
Neuroprotection-Amyloid Neurotoxicity
Neuroprotection-Excitotoxicity
Pharmacokinetics
Drug Concentration-Brain
Drug Concentration-Serum
Oral Bioavailability (F%)
Toxicology
Ames Test
hERG Assay
ADME
Caco-2 Absorption
CYP450 Inhibition